查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1842186

肝炎药物市场规模、份额和趋势分析报告：疾病、分销管道、地区和细分市场预测，2025-2033年

Hepatitis Therapeutics Market Size, Share & Trends Analysis Report By Disease (Hepatitis A, Hepatitis B, Hepatitis C), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

肝炎治疗市场摘要

全球肝炎治疗市场预计在 2024 年达到 168 亿美元，预计到 2033 年将达到 236.2 亿美元，2025 年至 2033 年的复合年增长率为 3.9%。

由于乙型和丙型肝炎感染的流行持续构成重大的健康挑战，全球市场正在不断扩大。

筛检的改进和临床意识的提高加速了早期诊断，从而有助于及时启动治疗。对抗病毒药物、直接抗病毒药物和免疫调节剂的需求仍然强劲，并构成了目前治疗的基石。例如，乙型肝炎基金会报告称，美国食品药物管理局（FDA）核准七种药物用于治疗慢性乙型肝炎，其中包括五种口服抗病毒药物：维瑞德（Viread）、维美利达（Vemlidy）、博来格列净（Baraclude）、艾匹维-HBV（Epivir-HBV）和博来格列净（Baraclude）、艾匹维-HBV（Epivir-HBV）和赫普塞拉（Hepsera），以及两种注射免疫剂用免疫调节剂。基金会强调，治疗方案的製定应考虑肝病活动度和肝硬化情况，并建议由专科医师定期监测。治癒性丙型肝炎药物的日益普及进一步增强了该领域的成长前景。

此外，未经治疗的肝炎感染导致肝臟相关併发症（如肝硬化和肝细胞癌）的增加，推动了对先进治疗方法的需求。与老化相关的併发症发生率不断上升，使得人们更加依赖疗效和安全性已得到证实的抗病毒疗法。製药公司正积极投资临床研究，以期透过治癒率更高、耐受性更好的治疗方法来满足这些需求。例如，2025年8月，《应用临床试验在线》（Applied Clinical Trials Online）报告，Aligos Therapeutics公司已启动了ALG-000184（一种First-in-Class的口服衣壳组装调变器）的II期B-SUPREME试验，该试验纳入了约200名治疗的成年患者，其中包括慢性HBe和阴性患者。这项随机、双盲试验旨在比较ALG-000184单药治疗与富马酸替诺福韦酯治疗48週的疗效，主要终点为HBV DNA抑制，次要终点包括安全性、药物动力学和抗原降低。中期结果预计于2026年公布，主要结果预计于2027年公布。先前的I期数据已证实ALG-000184具有持续的抗病毒活性、良好的安全性，且未发现新的安全性讯号，进一步推动了肝炎治疗领域的临床创新。

细胞免疫疗法的出现正在推动肝炎治疗市场的成长，尤其是在慢性感染疾病导致晚期肝臟併发症的患者中。例如，2025年5月，OncLive通报，自体HBV特异性T细胞疗法SCG101在晚期HBV相关肝细胞癌中展现出抗病毒和抗肿瘤活性。在一项I期临床试验中，94%的患者在28天内HBsAg水平显着降低，并维持控制长达一年，其中23.5%的患者实现了HBsAg完全清除。 47%的患者观察到肿瘤缓解，但尚未达到中位总存活期。安全性良好，最常见的不良事件为短暂性ALT升高和细胞激素释放症候群。这些结果凸显了创新免疫疗法在满足未被满足的医疗需求和促进市场扩张方面的重要作用。

目录

第一章调查方法和范围

第二章执行摘要

第三章 肝炎药物市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章 肝炎治疗市场：依疾病区分的业务分析

  • 按疾病分類的市场份额，2024 年和 2033 年
  • 疾病细分仪表板
  • 市场规模、预测与趋势分析：按疾病分类，2021-2033 年
  • 甲型肝炎
  • B型肝炎
  • C型肝炎
  • 其他的

第五章 肝炎治疗市场：依通路分類的业务分析

  • 按分销管道分類的市场份额，2024 年和 2033 年
  • 按分销管道分類的细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析，2021-2033年
  • 医院药房
  • 药局和药房
  • 其他的

第六章 肝炎治疗药物市场：区域估算与趋势分析

  • 2024 年及 2033 年区域市占率分析
  • 区域市场概览
  • 市场规模、预测与趋势分析：2021-2033年
  • 北美洲
    • 按国家/地区划分，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争情势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/上市公司
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd
    • Zydus Group
    • GSK plc.
    • AbbVie Inc.
    • Gilead Sciences, Inc.
    • Merck &Co., Inc.
    • Lupin
    • Cipla
Product Code: GVR-1-68038-449-9

Hepatitis Therapeutics Market Summary

The global hepatitis therapeutics market size was estimated at USD 16.80 billion in 2024 and is projected to reach USD 23.62 billion by 2033, growing at a CAGR of 3.9% from 2025 to 2033. The global market is expanding as the prevalence of hepatitis B and C infections continues to pose a significant health challenge.

Improved screening and rising clinical awareness have accelerated early diagnosis, supporting timely treatment initiation. Demand for antivirals, direct-acting antivirals, and immunomodulators remains strong, forming the backbone of current therapies. For instance, the Hepatitis B Foundation reported FDA approval of seven medications for chronic hepatitis B, including five oral antivirals: Viread, Vemlidy, Baraclude, Epivir-HBV, and Hepsera, along with two injectable immune modulators: Pegasys and Intron A. The foundation emphasized that treatment decisions should consider liver disease activity and cirrhosis, with regular specialist monitoring recommended. Rising adoption of curative hepatitis C therapies further strengthens growth prospects.

Another key driver is the rise in liver-related complications associated with untreated hepatitis infections, such as cirrhosis and hepatocellular carcinoma, which is pushing demand for advanced therapeutic approaches. The increasing burden of comorbid conditions in aging populations has heightened reliance on antiviral regimens with proven efficacy and safety. Pharmaceutical companies are actively investing in clinical research to address these needs through therapies with higher cure rates and improved tolerability. For instance, in August 2025, Applied Clinical Trials Online reported that Aligos Therapeutics had initiated dosing in its Phase II B-SUPREME trial of ALG-000184, a first-in-class oral capsid assembly modulator, in approximately 200 treatment-naive adults with chronic hepatitis B, including both HBeAg-positive and HBeAg-negative patients. The randomized, double-masked study was designed to compare ALG-000184 monotherapy with tenofovir disoproxil fumarate over 48 weeks, with primary endpoints focusing on HBV DNA suppression and secondary outcomes assessing safety, pharmacokinetics, and antigen reductions. Interim findings were expected in 2026, and topline results in 2027, while earlier Phase I data had already demonstrated sustained antiviral activity, favorable safety, and no new safety signals, reinforcing the momentum of clinical innovation in hepatitis therapeutics.

The emergence of cell-based immunotherapies is driving growth in the hepatitis therapeutics market, particularly for patients with advanced liver complications from chronic infections. For instance, in May 2025, OncLive reported that SCG101, an autologous HBV-specific T-cell therapy, delivered antiviral and antitumor activity in advanced HBV-related hepatocellular carcinoma. In a Phase I trial, 94% of patients achieved notable HBsAg reductions within 28 days, with sustained control for up to one year, while 23.5% achieved complete HBsAg loss. Tumor responses were observed in 47% of patients, and median overall survival had not been reached. Safety remained manageable, with transient ALT elevations and cytokine release syndrome being the most common events. These outcomes underscore the role of innovative immunotherapies in addressing unmet needs and strengthening market expansion.

Global Hepatitis Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hepatitis therapeutics market report based on disease, distribution channel, and region:

  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Hepatitis Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Hepatitis Therapeutics Market: Disease Business Analysis

  • 4.1. Disease Market Share, 2024 & 2033
  • 4.2. Disease Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
  • 4.4. Hepatitis A
    • 4.4.1. Hepatitis A Market, 2021 - 2033 (USD Million)
  • 4.5. Hepatitis B
    • 4.5.1. Hepatitis B Market, 2021 - 2033 (USD Million)
  • 4.6. Hepatitis C
    • 4.6.1. Hepatitis C Market, 2021 - 2033 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Hepatitis Therapeutics Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.5. Drug Stores and Retail Pharmacies
    • 5.5.1. Drug Stores and Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Hepatitis Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Hepatitis Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Type Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Type Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Type Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Type Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Type Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Type Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Type Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Type Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Type Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Type Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Type Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Type Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Type Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Type Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Type Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Type Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Type Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Type Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Type Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Type Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Type Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Type Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Type Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Hepatitis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Teva Pharmaceutical Industries Ltd.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Disease Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Bristol-Myers Squibb Company
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Disease Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. F. Hoffmann-La Roche Ltd
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Disease Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Zydus Group
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Disease Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. GSK plc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Disease Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. AbbVie Inc.
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Disease Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Gilead Sciences, Inc.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Disease Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Merck & Co., Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Disease Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Lupin
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Disease Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Cipla
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Disease Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global hepatitis therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 5 Global hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6 North America hepatitis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 8 North America hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9 U.S hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 10 U.S hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 Canada hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 12 Canada hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 Mexico hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 14 Mexico hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15 Europe hepatitis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 17 Europe hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18 UK hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 19 UK hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Germany hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 21 Germany hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22 France hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 23 France hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 Italy hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 25 Italy hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26 Spain hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 27 Spain hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28 Norway hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 29 Norway hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 Denmark hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 31 Denmark hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32 Sweden hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 33 Sweden hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific hepatitis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37 Japan hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 38 Japan hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 China hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 40 China hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41 India hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 42 India hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43 Australia hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 44 Australia hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 South Korea hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 46 South Korea hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47 Thailand hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 48 Thailand hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49 Latin America hepatitis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 51 Latin America hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Brazil hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 53 Brazil hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Argentina hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 55 Argentina hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Hepatitis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59 South Africa hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 60 South Africa hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63 UAE hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 64 UAE hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65 Kuwait hepatitis therapeutics market, by disease, 2021 - 2033 (USD Million)
  • Table 66 Kuwait hepatitis therapeutics market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Hepatitis therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Hepatitis therapeutics market dynamics
  • Fig. 12 Hepatitis therapeutics market: Porter's five forces analysis
  • Fig. 13 Hepatitis therapeutics market: PESTLE analysis
  • Fig. 14 Disease market, 2021 - 2033 (USD Million)
  • Fig. 15 Hepatitis A market, 2021 - 2033 (USD Million)
  • Fig. 16 Hepatitis B market, 2021 - 2033 (USD Million)
  • Fig. 17 Hepatitis C market, 2021 - 2033 (USD Million)
  • Fig. 18 Others market, 2021 - 2033 (USD Million)
  • Fig. 19 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 20 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 21 Drug store and retail pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 22 Others market, 2021 - 2033 (USD Million)
  • Fig. 23 Hepatitis therapeutics market revenue, by region
  • Fig. 24 Regional marketplace: Key takeaways
  • Fig. 25 North America hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 26 U.S. country dynamics
  • Fig. 27 U.S. hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 28 Canada country dynamics
  • Fig. 29 Canada hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 30 Mexico country dynamics
  • Fig. 31 Mexico hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 32 Europe hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 33 UK country dynamics
  • Fig. 34 UK hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 35 Germany country dynamics
  • Fig. 36 Germany hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 37 France country dynamics
  • Fig. 38 France hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 Italy country dynamics
  • Fig. 40 Italy hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 41 Spain country dynamics
  • Fig. 42 Spain hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 Norway country dynamics
  • Fig. 44 Norway hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 45 Sweden country dynamics
  • Fig. 46 Sweden hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 47 Denmark country dynamics
  • Fig. 48 Denmark hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 50 Japan country dynamics
  • Fig. 51 Japan hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 China country dynamics
  • Fig. 53 China hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 India country dynamics
  • Fig. 55 India hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 Australia country dynamics
  • Fig. 57 Australia hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 58 South Korea country dynamics
  • Fig. 59 South Korea hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 Thailand country dynamics
  • Fig. 61 Thailand hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 62 Latin America hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 63 Brazil country dynamics
  • Fig. 64 Brazil hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 Argentina country dynamics
  • Fig. 66 Argentina hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 MEA hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 68 South Africa country dynamics
  • Fig. 69 South Africa hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 70 Saudi Arabia country dynamics
  • Fig. 71 Saudi Arabia hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 72 UAE country dynamics
  • Fig. 73 UAE hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 Kuwait country dynamics
  • Fig. 75 Kuwait hepatitis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 76 Company categorization
  • Fig. 77 Company market position analysis
  • Fig. 78 Strategic framework